Doctors slam Kim Kardashian for promoting tanning beds in new viral TikTok video - despite skin cancer running in the family
Kim Kardashian [left] has taken heat from fans and doctors for promoting tanning beds. Dermatologists warned about the many health risks, especially given her family history of cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - January 18, 2024 Category: Consumer Health News Source Type: news
FDA Approves AI Device That Helps Spot Skin Cancer
THURSDAY, Jan. 18, 2024 (HealthDay news) -- The first medical device powered by artificial intelligence and designed to help doctors catch skin cancer has been approved by the U.S. Food and Drug Administration.Although not meant to be used as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 18, 2024 Category: General Medicine Source Type: news
AI-Powered Device Cleared as Noninvasive Skin Cancer Test AI-Powered Device Cleared as Noninvasive Skin Cancer Test
The handheld tool, intended for use by primary care physicians, uses spectroscopy and algorithms to evaluate skin lesions for potential cancer in a matter of seconds.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 17, 2024 Category: Dermatology Tags: Dermatology Source Type: news
FDA Clears AI-Powered Non-Invasive Skin Cancer Detector
(MedPage Today) -- The FDA cleared an artificial-intelligence (AI)-powered device designed to non-invasively detect skin cancer in the primary care setting, the agency announced on Tuesday.
Developer DermaSensor said the device uses AI-powered... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 17, 2024 Category: Dermatology Source Type: news
FDA Clears AI-Powered Handheld Device That Can Detect Skin Cancer
The FDA has approved a first-of-its kind, non-invasive device that detects the three most common types of skin cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 17, 2024 Category: Pharmaceuticals Authors: James Farrell, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
Coming Soon: The First mRNA Vaccine for Melanoma? Coming Soon: The First mRNA Vaccine for Melanoma?
Results of a phase 2b trial were favorable, and Moderna suggests that an mRNA vaccine for melanoma could be available in 2025.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 17, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Handheld Mole Imaging System
LOS GATOS, Calif., Jan. 16, 2024 -- (Healthcare Sales & Marketing Network) -- In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin Fluorescence Imaging (mSFI) System to n... Devices, Dermatology Orlucent , mSFI , molecular Skin Fluorescence Imaging, melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
New hope for skin cancer patients after scientists develop simple blood test for determining best possible treatment
The test, known as liquid biopsy, is currently at trial stage, but it is hoped that in the future it will be used regularly to aid doctors in making crucial decisions about when to start and stop different treatments. (Source: the Mail online | Health)
Source: the Mail online | Health - January 13, 2024 Category: Consumer Health News Source Type: news
Community Cancer Centers Treating More HPV-Related Head, Neck Cancer
THURSDAY, Jan. 11, 2024 -- Treatment of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2024 Category: Pharmaceuticals Source Type: news
Scientists destroy 99% of cancer cells in lab using this new technique
The early-stage research - which saw 99 per cent of melanoma cells eradicated in a lab - could provide new cancer treatment options, experts say. Scientists in the US have found a way to destroy cancer cells by stimulating molecules with near-infrared light and causing them to vibrate. The…#naturechemistry #ciceronayalaorozco #riceuniversity #euronewsnext #ayalaorozco #drnisharnthiduggan #scienceengagement #cancerresearch #nobel #bernardferingas (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2024 Category: Consumer Health News Source Type: news
NHS regulators clear new skin cancer drugs combo to treat patients who suffer gruelling side effects from current treatments
Sold under the brand name Opdualag, the blend of two drugs treats advanced melanoma - a crippling disease which kills more than 2,000 Britons a year. (Source: the Mail online | Health)
Source: the Mail online | Health - January 6, 2024 Category: Consumer Health News Source Type: news
The common skin cancer that could turn into deadly melanoma- as President Joe Biden shows off sunburned skin on return from Caribbean vacation less than a year after having cancerous lesion removed
President Joe Biden has already been warned off being burnt, after suffering basal cell carcinoma - a type of skin cancer - in February last year and several other bouts of the cancer before 2021. (Source: the Mail online | Health)
Source: the Mail online | Health - January 3, 2024 Category: Consumer Health News Source Type: news
PET/CT predicts brain tumors in melanoma patients
PET/CT scans have the potential to predict brain metastasis in melanoma patients, according to a study published December 26 in Cancers.
In a retrospective study, a team at the University Hospital Salzburg in Austria studied baseline F-18 FDG-PET/CT imaging parameters in patients with melanoma and found they were associated with the development of metastatic brain tumors.
“In melanoma patients, identification of those who are at higher risk of brain metastasis occurrence can be crucial as subsequent surveillance and even prophylactic treatment options can be provided,” wrote lead author and nuclear medicine physician...
Source: AuntMinnie.com Headlines - January 3, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Molecular Imaging Nuclear Radiology Source Type: news
